Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

CRISPR and CRISPR-Associated Gene Market Set to Surge to $20 Billion by 2035, Fueled by Technological Breakthroughs and Biotech Investments The global CRISPR and CRISPR-Associated Gene Market Size is ...

CRISPR Therapeutics has not performed well in the past year and a half since hitting that milestone. Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success. It recently won ...

Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is ...

Bluebird has reaffirmed its support for a proposed acquisition after Ayrmid failed to deliver a binding offer by the extended ...

Indian American physician-scientist and business executive Reshma Kewalramani, the CEO of Vertex Pharmaceuticals, has been ...

As previously reported, Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and a price target of ...

ToolGen commences legal action in UK court over Vertex's genome editing therapy, CASGEVY ® Seeks to expand licensing of its proprietary CRISPR RNP ... against Vertex Pharmaceuticals and its ...

In the latest market close, CRISPR Therapeutics AG (CRSP) reached $37.77, with a -0.03% movement compared to the previous day. This change lagged the S&P 500's 0.13% gain on the day. On the other ...

ToolGen commences legal action in UK court over Vertex's genome editing therapy, CASGEVY ® Seeks to expand licensing of its proprietary CRISPR RNP ... against Vertex Pharmaceuticals and its ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...